Educational content only. Not medical advice. Consult a qualified physician.
Elamipretide (SS-31) peptide
Anti-AgingInvestigational. Not currently FDA-approved. Has undergone multiple Phase II and Phase III clinical trials. Received FDA Fast Track and Orphan Drug designations for certain indications.

SS-31

Elamipretide (SS-31)

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Stealth BioTherapeutics. It selectively targets cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial function and reducing oxidative stress. It has been studied in clinical trials for several mitochondrial and age-related diseases.
Reported Benefits

Potential Benefits

  • Targets and stabilizes cardiolipin in the inner mitochondrial membrane
  • Clinical trials have studied its effects in heart failure, Barth syndrome, and mitochondrial myopathy
  • Research suggests potential to improve mitochondrial ATP production efficiency
  • May reduce mitochondrial-derived reactive oxygen species
  • Preclinical data indicates potential benefits for age-related organ decline
Research Dosing

Recommended Starting Dose

Clinical trial doses have ranged from 4 mg to 40 mg IV or subcutaneously (not established for general use)

Based on published research protocols. Not a prescription.

Dosing Protocol

In clinical trials, elamipretide has been administered as daily subcutaneous injections (typically 40 mg) or intravenous infusions. Dosing protocols are specific to the clinical trial indication. This is not a compound with established consumer dosing.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Clinical trial endpoints have varied by indication. Some trials measured acute effects (hours to days), while others assessed outcomes over 24-48 weeks.

Regulatory

Research Status

Investigational. Not currently FDA-approved. Has undergone multiple Phase II and Phase III clinical trials. Received FDA Fast Track and Orphan Drug designations for certain indications.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Injection site reactions reported in clinical trials
  • Headache
  • Nausea
  • Fatigue
  • Clinical trial results have been mixed, with some failing primary endpoints
  • Long-term safety profile is still being characterized
Related Research

More in Anti-Aging

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.